Skip to Main Content

INFORMATION FOR

    Amin Nassar, MD

    Clinical Fellow
    DownloadHi-Res Photo

    About

    Titles

    Clinical Fellow

    Biography

    Amin Nassar, M.D., is a hematology/oncology fellow at Yale University. He received his medical degree from the American University of Beirut and completed residency at Brigham and Women’s Hospital. Dr. Nassar also pursued a two-year postdoctoral training at Brigham and Women’s Hospital where he worked under the mentorship of Professors Dr. David Kwiatkowski, Dr. Toni Choueiri, and Dr. Matthew Freedman at Harvard Medical School. His research focuses on the identification of genomic biomarkers across ancestral populations with cancer. Dr. Nassar currently serves on the editorial board of “Molecular biology reports”, “Translational oncology”, and “Frontiers in Oncology”. He is also one of the Associate Guest editors for the journal “Frontiers in Oncology”. He has published >50 original articles, 20 as first or co-first author, which include, as detailed below, first-author papers in Nature Communications, Cancer Cell, Journal of Clinical Oncology, Journal of Thoracic Oncology, JNCI, and The New England Journal of Medicine. He has also been an invited speaker to several conferences including AACR, XXIV SBOC, Korean Society of Medical Oncology, and Prostate Cancer Foundation. Dr. Nassar is interested in a career as a physician-scientist with a clinical focus in thoracic oncology. He is currently pursuing a PhD in tumor immunology at the Flavell lab.

    Appointments

    • Medical Oncology and Hematology

      Clinical Fellow
      Primary

    Other Departments & Organizations

    Education & Training

    Internal Medicine
    Brigham and Women's Hospital (2022)
    MD
    American University of Beirut (2017)

    Research

    Overview

    • Along with his colleagues, Dr. Nassar showed in a study published in "Cancer Cell" that tumor-only sequencing overestimates TMB especially in non-Europeans and developed a methodology to recalibrate TMB calculation by ancestry. They also showed that TMB may not be a biomarker predictive of clinical benefit in non-Europeans.
    • Dr. Nassar described the prevalence of KRASG12C mutations across sex, race, and cancer types. This work was published in the “The New England Journal of Medicine”.
    • Dr. Nassar found that NGS calling for mismatch repair deficiency is more sensitive than IHC. He showed that the subset of patients with MMR-D missed by IHC and detected by NGS have similar outcomes to patients that are detected by IHC. He was the senior author of this work published in "Cancer Cell".
    • Dr. Nassar led a multicenter study shothat consolidation EGFR TKI offers superior PFS compared to durvalumab or observation among patients with unresectable stage III NSCLC treated with concurrent chemoradiation.
    • Along with his colleagues, Dr. Nassar identified differences in the germline landscape among continental ancestries with renal cell carcinoma.

    Medical Research Interests

    Allergy and Immunology; Biomarkers, Tumor; Epigenomics; Genetics, Population

    Research at a Glance

    Yale Co-Authors

    Frequent collaborators of Amin Nassar's published research.

    Publications

    2023

    2022

    Academic Achievements & Community Involvement

    • activity

      Frontiers in Oncology

    • activity

      Molecular Biology Reports

    • activity

      Translational Oncology

    • activity

      Clinical Genitourinary cancer

    • activity

      Therapeutic Advances in Medical Oncology